Continue until either your weight begins to creep up or you reach the lowest available dose
The gradual approach allows your body to adjust
Within the same period, the dispensed prescriptions within the benefit to incident patients with a preexisting diagnosis of obesity without T2DM increased by 270% (4.0 to 14.6%), and 502% for patients with neither obesity nor T2DM (5.3 to 32.1%), and 515% for patients without any of the included diagnoses (4.2 to 25.7%) (see Table 9 in the Appendix)
50,53,54 In population pharmacokinetic models using data from trials with oral or subcutaneous administration of semaglutide, body weight had an effect on semaglutide pharmacokinetics, which did not warrant dose adjustment
It simultaneously activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors